Prelude Therapeutics INC (PRLD) — 10-Q Filings

10-Q Filings (6)

• Prelude Narrows Losses, Boosts Revenue Amid Strategic R&D Shift — Nov 12, 2025 Risk: high
  Prelude Therapeutics Inc. reported a net loss of $19.725 million for the three months ended September 30, 2025, a significant improvement from the $32.271 milli
• Prelude Therapeutics' Cash Dwindles Amidst Mounting Losses — Aug 14, 2025 Risk: high
  Prelude Therapeutics Inc. reported a net loss of $31.2 million for the three months ended June 30, 2025, an improvement from a net loss of $34.7 million in the
• Prelude Therapeutics Files Q1 2025 10-Q — May 6, 2025 Risk: medium
  Prelude Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first qu
• Prelude Therapeutics Files Q3 2024 10-Q — Nov 6, 2024 Risk: medium
  Prelude Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and business operations. Key
• Prelude Therapeutics Files Q2 2024 10-Q — Aug 12, 2024 Risk: low
  Prelude Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company's financial statements and disclosures are presented, including detail
• Prelude Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: low
  Prelude Therapeutics Inc (PRLD) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Filed a 10-Q report for the period ending March 31, 2024. The filin

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX